SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as Novo Nordisk files a lawsuit over alleged unapproved GLP-1 copycats, leading Hims to halt its compounded weight-loss pill amid regulatory scrutiny and sparking intense community debate on the company's prospects.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following a $250 million capital commitment designed to extend its operational runway through 2028, sparking intense community debate between those who see it as a strong foundation for its traceability technology and critics wary of past dilution and extreme volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is actively discussed as its Eagle Line pilot production goes live, with a viral tech video sparking community debate on the company's solid-state battery advancements, potential OEM partnerships, and the path to commercialization ahead of its anticipated earnings.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following its mixed financial results, which showed solid profitability but offered a conservative revenue outlook for future periods, sparking a significant sell-off. The community is sharply divided, with many decrying the market's "ridiculous overreaction" and viewing the dip as a generational buying opportunity, while others remain cautious regarding the revised guidance.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com (MNDY) is trending sharply lower after providing a weaker-than-expected revenue outlook, despite beating Q4 earnings and revenue estimates. The community is actively debating whether this sell-off is an overreaction or a legitimate concern that AI advancements pose a significant threat to its business model.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is a key topic of conversation after its 4M Defense subsidiary secured a substantial $30 million multi-year demining contract in Israel, which significantly boosts its defense backlog and fuels community speculation about an imminent short squeeze despite broader market weakness.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending due to its highly engaged community driving the "OG meme" narrative, positioning itself as a foundational reset for the crypto market. Enthusiasts exhibit strong conviction, actively building platforms like RageMaker and RageGames, and rallying others to "Return to the Memes" and "Rage On" to assert cultural dominance.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending after cutting its earnings outlook and disclosing a financial reporting review by the SEC, alongside executive exits, which has led the community to speculate about potential financial irregularities and bankruptcy, while others see an overblown market reaction for the IBM spin-off in the evolving IT services sector.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean's all-stock agreement to acquire Valaris aims to create an offshore drilling industry leader poised for an emerging upcycle, sparking community debate over whether this strategic consolidation will reduce debt and ignite a short squeeze despite the immediate negative stock reaction.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending following its Q4 earnings, where an EPS beat was overshadowed by a revenue miss, though management's optimistic 2026 guidance for improved steel prices and a value-accretive expiring slab contract is fueling discussion. The community is highly focused on the anticipated strategic partnership with POSCO and whether this, combined with favorable trade policies, will finally drive a significant turnaround for the steel producer.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for Jan. 13

ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

<ul class="summary-bullets"><li>GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant depression on Monday.</li><li>The update follows the company’s submission of a complete response to the FDA after a prior clinical hold.</li><li>Progress across competing psychedelic-based depression programs has increased focus on the stock.</li></ul>Shares of GH Research PLC drew increased retail attention on Monday ahead of a scheduled update on its FDA Investigational New Drug application for GH001, the company’s inhaled therapy for treatment-resistant depression, and its plans for a global Phase 3 program, due at 7:00 a.m. EST.<h2 class="st-heading-2">Phase 3 Program And FDA Update In Focus</h2>The update follows the company’s June disclosure that it submitted a complete response to the FDA addressing a previously announced clinical hold on the IND. At the time, GH Research said the submission included completed toxicology studies and comprehensive responses to the agency’s requests, adding that it had worked closely with regulators and submitted the response ahead of schedule.<h2 class="st-heading-2">GH001 Data Anchors Development Path</h2>GH001 is GH Research’s lead experimental therapy, delivered through a proprietary inhalation system and designed to treat patients with treatment-resistant depression, a condition where standard antidepressants have failed.In February 2025, the company reported results from a Phase 2b study involving 81 patients. Those treated with GH001 showed a significant improvement in depression symptoms within eight days, with scores on a standard clinical scale falling by an average of 15.5 points more than placebo. The difference was statistically significant.Over half of the patients receiving GH001 achieved remission by Day 8, compared with none in the placebo group. The company said all secondary study goals were met, and the treatment was well tolerated, with no serious adverse events reported during the blinded phase of the trial.Longer-term follow-up data showed sustained benefits. Among patients who completed six months of follow-up, nearly 78% remained in remission, with most requiring only a small number of additional treatments. As of late January 2025, the company reported no serious safety issues during this extended period.<h2 class="st-heading-2">Psychedelic Race Intensifies</h2>In November, H.C. Wainwright lowered its price target on GH Research to $35 from $40 while maintaining a ‘Buy’ rating, citing competitive momentum from programs such as Atai Beckley’s BPL-003 and AbbVie’s GM-2505, as well as the prior FDA hold.In October, Needham initiated coverage with a ‘Buy’ rating and a $19 price target, citing GH001’s Phase 2 efficacy and remission data and estimating potential U.S. sales of $1.9 billion by 2035.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for GH Research was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/ghrs_ss_png_215c6b80c9.webp" alt="ghrs ss.png" width="968" height="143"><figcaption>GHRS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user grouped GH Research alongside names like Disney, Marathon Digital, Critical Metals and Navitas Semiconductor, saying the stock continues to sit within a cluster of “hot themes” across the market.<stembedurl>https://stocktwits.com/JoyceFernandez/message/640797658</stembedurl>Another user said they plan to sell part of their position around the FDA update to lock in gains and hold the rest into the next company update later in the quarter.<stembedurl>https://stocktwits.com/NoobFriendly/message/640797043</stembedurl><a href="https://stocktwits.com/symbol/GHRS">GH Research’s stock</a> has risen 89% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the GH Research logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

Equity

<ul class="summary-bullets"><li>The analyst noted that sponsors must continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health.</li><li>Jefferies added that it believes Atai Beckley's (ATAI) proprietary psychedelics have promise.</li><li>The AdvisorShares Psychedelics ETF (PSIL), which invests in the emerging psychedelic drugs sector, traded 1.3% higher at the time of writing.</li></ul>Jefferies analyst Andrew Tsai now sees positive tailwinds forming for non-recreational psychedelics after President Trump signed an executive order on Thursday directing his administration to reclassify marijuana.The firm now sees non-recreational psychedelics eventually follow suit, as long as sponsors continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health. This, the analyst believes, is arguably a function of time.&nbsp;Jefferies added that it believes pharmaceutical company Atai Beckley's (<a href="https://stocktwits.com/symbol/ATAI">ATAI</a>) proprietary psychedelics have promise. AtaiBeckley’s pipeline includes investigational therapies for treatment-resistant depression and social anxiety disorder.Shares of psychedelics-related stocks rallied on Friday. While ATAI stock traded 0.4% higher at the time of writing, Supernus (<a href="https://stocktwits.com/symbol/SUPN">SUPN</a>) and Cybin (<a href="https://stocktwits.com/symbol/CYBN">CYBN</a>) shares rose about 5%.The AdvisorShares Psychedelics ETF (<a href="https://stocktwits.com/symbol/PSIL">PSIL</a>), which invests in the emerging psychedelic drugs sector, also traded 1.3% higher.<h2 class="st-heading-2">Trump Cannabis Order</h2>President Donald Trump on Thursday <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-stock-rise-as-trump-signs-executive-order-to-lower-marijuana-restrictions/cLegUFuREr0">signed</a> an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.” Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. The Centers for Medicare &amp; Medicaid Services (CMS) is also working on a plan to test making some Medicare patients eligible for therapies derived from cannabinoids or compounds derived from the Cannabis plant.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PSIL fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while sentiment around ATAI also took a dip to ‘extremely bearish’ levels.Sentiment around SUPN stayed ‘neutral,’ while sentiment around CYBN stayed ‘extremely bullish’.A Stocktwits user highlighted a positive study from 2022 on Psilocybin, a naturally occurring psychedelic compound, in treating depression symptoms.<stembedurl>https://www.stocktwits.com/DJS777/message/639663641</stembedurl>As per the study published in the New England Journal of Medicine, participants reported a greater reduction in levels of depression three weeks after taking a 25 mg dose of psilocybin, compared to those who took the lowest 1 mg dose.PSIL has gained 68% this year and by 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-on-track-for-worst-day-in-about-9-months/cLe0RFtREsu">Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.  

Enhanced Fortifies Executive Leadership Team & Board of Directors

Enhanced Fortifies Executive Leadership Team & Board of Directors Enhanced Fortifies Executive Leadership Team & Board of Directors PR Newswire NEW YORK, Nov. 19, 2025 Co-Founder Maximilian Martin...

atai Life Sciences (ATAI) Upgraded to Buy: Here's Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Halozyme Therapeutics (HALO) This Year?

Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now

atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

ATAI
ATAI Life Sciences N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATAI News

ATAIATAI Life Sciences N.V.